SVF
Level D· Preclinical EvidenceLaboratory Study

Dose-dependent biphasic effect of environmental UVA on stem cell function through PRPF40A, TGF-β1, NFATc1 signaling.

Zheng Q., Ngo HTT., Nguyen TTM., Kim JW., Choi JW., Yi TH.

Laboratory Study on Face & Skin, Hair & Scalp, Hip, published in J Photochem Photobiol B (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
J Photochem Photobiol B (2026)
Country
Switzerland
Reported sample size
—
PMID
41950867
DOI
10.1016/j.jphotobiol.2026.113435

Abstract (original English)

Solar ultraviolet A (UVA) radiation makes up nearly 95% of the ultraviolet spectrum at the Earth's surface, forming a major environmental exposure. High-dose UVA is a well-established driver of phototoxicity and tissue degeneration; however, the impact of low-dose UVA on stem-cell homeostasis remains incompletely defined. Here, we investigated whether UVA elicits a dose-dependent biphasic response in human adipose-derived mesenchymal stem cells (AMSCs) and evaluated PRPF40A as a molecular indicator of stemness status. AMSCs were exposed to single or fractionated UVA regimens (0.05-2 J/cm 2 ), followed by assessments of viability, migration, oxidative stress, apoptosis and senescence, stemness programs, multilineage differentiation, and secretome remodeling. In cultured human AMSCs, UVA induced a biphasic dose-response pattern. An ultra-low dose (0.05 J/cm 2 ) enhanced viability and migratory capacity, reduced basal reactive oxygen species, preserved NANOG/SOX2/OCT4 expression, and promoted chondrogenic potential. In contrast, doses of 0.5 J/cm 2 or higher, particularly under cumulative exposure, induced oxidative injury, apoptosis, senescence-like changes, reduced stemness, impaired differentiation, and a pro-inflammatory senescence-associated secretory phenotype. Mechanistically, PRPF40A was inversely associated with stemness and showed dose-dependent co-regulation with TGF-β1

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence comes from animal or laboratory studies and has not been confirmed in humans.

How we grade evidence
HumansUltraviolet RaysMesenchymal Stem CellsSignal TransductionTransforming Growth Factor beta1Cell DifferentiationNFATC Transcription FactorsApoptosisCell SurvivalCell Movement
Face & SkinHair & ScalpHip
View on PubMedDOI

Related research